@misc{85e73de67c7b4fe8a9dbdc7af70fe15a,
title = "e-Science, caGrid, and translational biomedical research",
abstract = "Translational research projects target a wide variety of diseases, test many different kinds of biomedical hypotheses, and employ a large assortment of experimental methodologies. Diverse data, complex execution environments, and demanding security and reliability requirements make the implementation of these projects extremely challenging and require novel e-Science technologies.",
keywords = "Bioinformatics, Cancer, Data models, Diseases, Genetics, Genomics, Interoperability, Pattern templates, Translational biomedical research, Tumors, caGrid, e-Science",
author = "Joel Saltz and Tahsin Kurc and Shannon Hastings and Stephen Langella and Scott Oster and David Ervin and Ashish Sharma and Tony Pan and Metin Gurcan and Justin Permar and Renato Ferreira and Philip Payne and Umit Catalyurek and Enrico Caserta and Gustavo Leone and Ostrowski, {Michael C.} and Ravi Madduri and Ian Foster and Subhashree Madhavan and Buetow, {Kenneth H.} and Krishnakant Shanbhag and Eliot Siegel",
note = "Funding Information: We thank Laura Esserman and Nola Hylton at the University of California, San Francisco, the PIs for the I-SPY trial project; Howard Fine at the NCI, the PI for the GMDI and Rembrandt projects; and Stephen Cha-nock, NCI, the PI for the CGEMS (GWAS) project. Our work was supported in part by the NCI caGrid Developer grant 79077CBS10, the State of Ohio BRTT Program grants ODOD AGMT TECH 04-049 and BRTT02-0003, the NHLBI R24 HL085343 grant, the NIH U54 CA113001 and R01 LM009239 grants, and NSF grants CNS-0403342 and CNS-0615155; by the NCI and NIH under contract no. N01-CO-12400; by the US Department of Energy under contract DE-AC02-06CH11357; and by Children{\textquoteright}s Neuroblastoma Cancer Foundation. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. Funding Information: The integrative template involves patient-related studies attempting to predict and explain patient response to treatment protocols by collecting and analyzing comprehensive sets of high-throughput molecular data, image data, and clinical data. Researchers can use the integrative template to model large-scale projects such as the Glioma Molecular Diagnostic Initiative (GMDI; http:// bethesdatrials.cancer.gov/neuro_oncology/nci02c0140/ default.aspx), the Cancer Genome Atlas project (TCGA; http://cancergenome.nih.gov), the Cancer Genetic Markers of Susceptibility (CGEMS; http://cgems.cancer.gov) project, and the I-SPY breast cancer trial (http://ncicb. nci.nih.gov/tools/translation_research/ispy). GMDI, funded by the National Cancer Institute (NCI), studies gene expression and genomic data from patients afflicted with tumors (gliomas). Researchers will follow these patients through the natural history and treatment phases of their illness. The GMDI seeks to develop a molecular classification schema that is both clinically and biologically meaningful and to explore gene expression profiles to determine the patients{\textquoteright} responsiveness and correlate it with discrete chromosomal abnormali- ties. TCGA is a large-scale community resource project cofunded by the NCI and National Human Genome Research Institute.",
year = "2008",
doi = "10.1109/MC.2008.459",
language = "English",
volume = "41",
pages = "58--66",
journal = "Computer",
issn = "0018-9162",
}